http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102472752-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-042 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-2871 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-324 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-585 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6893 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 |
| filingDate | 2010-08-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2015-08-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2015-08-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-102472752-B |
| titleOfInvention | For the Procalcitonin of the prognosis of adverse events |
| abstract | The present invention relates to the in-vitro method for carrying out prognosis in asymptomatic object to adverse events, it to comprise in the body fluid sample measuring described object Procalcitonin (PCT) or it has the fragment of at least 12 amino acid residues or the level of precursor or its fragment, and sets up correlativity between measured level and the potential risk suffering from adverse events. |
| priorityDate | 2009-08-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 207.